2025 US-Asia Technology Management Center Annual Meeting

US-ATMC Director Dr. Richard Dasher will present a review of US-ATMC programs and accomplishments with focus on the past year and also present our strategic overview of the Center’s plans for the 2025 – 26 academic year. Keynote speaker Dr. Bruce Ling, Senior Research Scientist, Stanford Pediatrics – Neonatology,  will introduce his research at Stanford into genomic data analytics for disease prediction. Following special presentations about collaborative US-ATMC research by Director Dasher and US-ATMC visiting scholars, the program will conclude with brief activities updates by US-ATMC visiting scholars.

Agenda:

• 4:30 PM US-ATMC Update and Strategic Overview from Dr. Richard Dasher, US-ATMC Director
• 4:45 PM  Keynote from Dr. Bruce Ling, Senior Research Scientist, Pediatrics – Neonatology
• 5:20 PM  Introductions to research by current US-ATMC visiting scholars

Registration:

• In-person: please register on Eventbrite here.
• Zoom: please register here.

About Dr. Bruce Ling:

Dr. Ling’s investigative interests are in translation medicine that bridge mass spectrometry based high throughput biology and biomedical computation. He brings a great depth of experience and demonstrated success in using his high throughput and high content multi-omics approach to create both platforms and products with obvious translational utility.

Dr. Ling earned his PhD in Biological Chemistry in UCLA with Dr. Michael Grunstein, a member of National Academy of Sciences. After graduation, Dr. Ling did a post-doc in molecular immunology under Dr. Alan Krensky at Stanford Medicine and simultaneously trained in computer science. With the unique computational skills and knowledge of the underlying biology, Dr. Ling’s professional career launched in the early days of the human genome project completion to decode for innovative drug targets. Bruce quickly advanced over the course of five years from a Bioinformatics Scientist to Research Director at Tularik Inc, an early and highly successful biotechnology start-up founded by Dave Goeddel who is legendary in the biotechnology field. When Tularik was acquired by Amgen, Dr. Ling stayed on at Amgen as Director of Research. Dr. Ling returned to Stanford in 2006 and brought with him his industry experience in creating high throughput laboratory and computational platforms for high content biomedical discoveries. During his tenure at Stanford, Dr. Ling has been instrumental in creating the mass spectrometry based infrastructure and associated computational platform to support diagnostic biomarker discovery and more recently in providing mechanism of disease insight. Throughout his career both in industry and academia, Dr. Ling has maintained a passion for mentoring others. His CV details a long list of highly successful trainees and students. It is also apparent that Dr. Ling has established numerous fertile collaborations both within the Stanford community as well as with other leading scientists in academia and industry.